外科領域におけるCefoxitinの基礎的・臨床的検討 (Cefoxitin論文特集号)
スポンサーリンク
概要
- 論文の詳細を見る
The present paper reports the results of evaluation of cefoxitin (CFX), a new semisynthetic cephamycin antibiotic.<BR>1) Sensitivity distribution, expressed in terms of MIC values, of various clinical isolates to cefoxitin: ten strains of <I>Staphylococcus aureus</I>; MICs were 12.5μg/ml or less with a peak of distribution at 3.13μg/ml. Among Gram-negative rods, 24 strains of <I>E. coli</I>; MIC distribution was similar to that of CEZ and 60% of the strains was inhibited at 12.5μg/ml or less. Against 12 strains of <I>Klebsiella</I>: the results were favourable showing MICs of 12.5μg/ml or less with a peak at 6.25μg/ml. Against species of the genera <I>Enterobacter</I>, <I>Serratia</I> and <I>Pseudomonas</I>, MICs were all 100μg/ml or more and clinical effects of CFX would not be expected to be demonstrated.<BR>2) Concentration of CFX in serum and bile of human. Following drip infusion of 1 g of CFX in 5% glucose solution in 1 hour, a peak serum level was 30μg/ml at the end of infusion. A peak level of 72μg/ml in bile was reached 2 to 3 hours after drip infusion of 1g in 2 hours.<BR>3) Clinical responses obtained were: excellent in 4, good in 3 and poor in 1 out of 8 cases.<BR>4) Slight elevations of S-GOT and S-GPT were observed in 2 patients to whom blood transfusions and administration of anti-cancer remedies were applied. These elevations of transaminase were not considered to be related to CFX. From the aforementioned results, it was thought that CFX might be a key weapon in the treatment for Gram-negative rod infections in surgical fields especially of the bile duct and other infections caused by <I>E. coli</I> and <I>Klebsiella</I> which have been increasing remarkably.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.